These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24885090)

  • 21. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
    Nunes V; Cazzaniga G; Biondi A
    Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients.
    Soverini S; De Benedittis C; Papayannidis C; Polakova KM; Venturi C; Russo D; Bresciani P; Iurlo A; Mancini M; Vitale A; Chiaretti S; Foà R; Abruzzese E; Sorà F; Kohlmann A; Haferlach T; Baccarani M; Cavo M; Martinelli G
    Leukemia; 2016 Jul; 30(7):1615-9. PubMed ID: 26867670
    [No Abstract]   [Full Text] [Related]  

  • 23. [Real-time quantitative study of minimal residual disease in childhood B cell acute lymphoblastic leukemia].
    Jia YP; Liu GL; Zhang LP
    Zhonghua Er Ke Za Zhi; 2004 Aug; 42(8):600-4. PubMed ID: 15347448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of Next-Generation Sequencing-Based Mutational Profiling in Acute Lymphoblastic Leukemia.
    Aleem A; Haque AR; Roloff GW; Griffiths EA
    Curr Hematol Malig Rep; 2021 Oct; 16(5):394-404. PubMed ID: 34613552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.
    Sala Torra O; Othus M; Williamson DW; Wood B; Kirsch I; Robins H; Beppu L; O'Donnell MR; Forman SJ; Appelbaum FR; Radich JP
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):691-696. PubMed ID: 28062215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival.
    Logan AC; Vashi N; Faham M; Carlton V; Kong K; Buño I; Zheng J; Moorhead M; Klinger M; Zhang B; Waqar A; Zehnder JL; Miklos DB
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1307-13. PubMed ID: 24769317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Test trial of spike-in immunoglobulin heavy-chain (IGH) controls for next generation sequencing quantification of minimal residual disease in acute lymphoblastic leukaemia.
    Giusti GNN; Jotta PY; Lopes CO; Ganazza MA; de Azevedo AC; Brandalise SR; Meidanis J; Yunes JA
    Br J Haematol; 2020 May; 189(4):e150-e154. PubMed ID: 32187384
    [No Abstract]   [Full Text] [Related]  

  • 28. Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia.
    Della Starza I; De Novi LA; Santoro A; Salemi D; Tam W; Cavalli M; Menale L; Soscia R; Apicella V; Ilari C; Vitale A; Testi AM; Inghirami G; Chiaretti S; Foà R; Guarini A
    Leuk Lymphoma; 2019 Nov; 60(11):2838-2840. PubMed ID: 31050551
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical application of next-generation sequencing-based monitoring of minimal residual disease in childhood acute lymphoblastic leukemia.
    Mai H; Li Q; Wang G; Wang Y; Liu S; Tang X; Chen F; Zhou G; Liu Y; Li T; Wang L; Wang C; Wen F; Liu S
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3259-3266. PubMed ID: 35918464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.
    van Dongen JJ; van der Velden VH; Brüggemann M; Orfao A
    Blood; 2015 Jun; 125(26):3996-4009. PubMed ID: 25999452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of rearranged T-cell receptor beta-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis.
    Kneba M; Bolz I; Linke B; Hiddemann W
    Blood; 1995 Nov; 86(10):3930-7. PubMed ID: 7579363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.
    Brüggemann M; van der Velden VH; Raff T; Droese J; Ritgen M; Pott C; Wijkhuijs AJ; Gökbuget N; Hoelzer D; van Wering ER; van Dongen JJ; Kneba M
    Leukemia; 2004 Apr; 18(4):709-19. PubMed ID: 14961040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of novel, recurrent genomic rearrangements as sensitive MRD targets in childhood B-cell precursor ALL.
    Zur Stadt U; Alawi M; Adao M; Indenbirken D; Escherich G; Horstmann MA
    Blood Cancer J; 2019 Nov; 9(12):96. PubMed ID: 31784504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clonal evolution as judged by immunoglobulin heavy chain gene rearrangements in relapsing precursor-B acute lymphoblastic leukemia.
    Rosenquist R; Thunberg U; Li AH; Forestier E; Lönnerholm G; Lindh J; Sundström C; Sällström J; Holmberg D; Roos G
    Eur J Haematol; 1999 Sep; 63(3):171-9. PubMed ID: 10485272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Minimal/Measurable Residual Disease Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor.
    Tung JK; Jangam D; Ho CC; Fung E; Khodadoust MS; Kim YH; Zehnder JL; Stehr H; Zhang BM
    J Mol Diagn; 2023 Jun; 25(6):331-341. PubMed ID: 36870603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VDJSeq-Solver: in silico V(D)J recombination detection tool.
    Paciello G; Acquaviva A; Pighi C; Ferrarini A; Macii E; Zamo' A; Ficarra E
    PLoS One; 2015; 10(3):e0118192. PubMed ID: 25799103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-cell receptor delta gene recombination in common acute lymphoblastic leukemia: preferential usage of V delta 2 and frequent involvement of the J alpha cluster.
    Yokota S; Hansen-Hagge TE; Bartram CR
    Blood; 1991 Jan; 77(1):141-8. PubMed ID: 1898632
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Considerations for monitoring minimal residual disease using immunoglobulin clonality in patients with precursor B-cell lymphoblastic leukemia.
    Jo I; Chung NG; Lee S; Kwon A; Kim J; Choi H; Jang W; Kim S; Lee JW; Yoon JH; Cho B; Han K; Kim Y; Kim M
    Clin Chim Acta; 2019 Jan; 488():81-89. PubMed ID: 30389459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IMGT/JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs.
    Yousfi Monod M; Giudicelli V; Chaume D; Lefranc MP
    Bioinformatics; 2004 Aug; 20 Suppl 1():i379-85. PubMed ID: 15262823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.